You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

374 Results
Guidelines and Advice
Status: Current
Version: 1
Aug 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - In Combination with Carboplatin and Paclitaxel for First-Line Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2022
Guidelines and Advice
Status: Current
Version: N/A
Aug 2019
Guidelines and Advice
Status: Current
ID: GL 3-20
Version: N/A
Aug 2019
Guidelines and Advice
Status: Current
Version: 1
Aug 2019
Guidelines and Advice
Status: Current
ID: 21-4
Version: N/A
Aug 2019
Cancer facts
Sep 2019
Guidelines and Advice
Status: Current
Version: 1
Apr 2019
Guidelines and Advice
Status: Current
Version: 2
Mar 2022
Guidelines and Advice
Status: Current
Version: 2
Mar 2022
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
CISplatin,
gemcitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell, 
Rare Diseases
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2019

Pages